I would have gladly seated you some time

Wilfred.

Welcome to Fast Money, I'm Melissa Lee.

Your traders for the hour, Guy Dami, Tim Seymour,

Karen Finerman, and C Graso coming up on Fast,

Steve Eisman of big short fame,

his take on the market turmoil

and where he is spotting the next big opportunity right now.

Plus, an earnings alert on Intel shares

are moving lower by about 5.5%.

As the company's conference call gets underway, we will bring

you the big headlines. And later, Barstool Trade School, the founder of Barstool Sports is

with us. He started day trading just a few weeks ago and he's down more than

half a million dollars but he's in luck. Our traders are here to help him fix his

portfolio but we start off with the major news on Gilead that weighed on the major averages today.

Gilead dropping on reports that company's coronavirus drug room, DeSevir, flopped in its first clinical trial.

Let's get straight to Meg Terrell with all the details.

Meg.

Hey Mel, so this is yet another piece of data coming out about Gilead's Drugram DeSevir

that's difficult to parse through because it was from a halted clinical trial coming out of

China that didn't enroll enough patients to finish but basically what happened was

a synopsis of these partial results essentially was posted by the World Health Organization

...